Key points are not available for this paper at this time.
Background: The phase 1 cohorts (1c+1d) of CheckMate 143 (NCT02017717) evaluated the safety/tolerability and efficacy of nivolumab plus radiotherapy (RT) ± temozolomide (TMZ) in newly diagnosed glioblastoma. Methods: = 30). Primary endpoint was safety/tolerability; secondary endpoint was overall survival (OS). Results: promoter. Conclusions: methylation status were observed.
Omuro et al. (2022) studied this question.